News

Market & Business

CONFIRMED: Isomorphic Labs raises $5 billion to speed up AI-designed medicines

The AI drug discovery company founded by Demis Hassabis closed a $5 billion Series C round led by Greenoaks and Sequoia, with continued backing from Alphabet, to scale its drug design engine.

Ilustração editorial sobre investimento em IA aplicada à biotecnologia

CONFIRMED

Isomorphic Labs, the AI drug discovery company founded by Demis Hassabis, confirmed on Tuesday, November 17, a $5 billion Series C round. Hassabis announced the investment himself on his X account, and the company published an official statement detailing its investors. The funding will finance the company's proprietary drug design engine, called IsoDDE, short for Isomorphic Drug Design Engine, and its pipeline of AI-designed therapeutic candidates.

A pipeline of AI-designed medicines

Isomorphic Labs was born inside DeepMind, the same AI lab Hassabis runs within Alphabet, Google's parent company. The company's proposition is to use AI models to predict how molecules behave inside the human body and design drug candidate compounds before any physical laboratory testing. It is the same kind of problem that earned Hassabis the 2024 Nobel Prize in Chemistry for his work on AlphaFold, the system that predicts protein structures. The difference now is scale: the company says it is expanding its therapeutic candidate pipeline across multiple diseases at once.

Who is footing the bill

The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and several other new investors. Alphabet, Google's parent company, maintained significant, continued investment. All existing investors also participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The official statement does not disclose the company's valuation after the round, only the amount raised.

Why this matters beyond biotech

Drug discovery is a niche far from the chatbot most people use every day, but the round matters as a thermometer: it shows major funds remain willing to bet billions on specialized AI applications, not only general-purpose models. Hassabis now holds two leading roles in the AI race, Google DeepMind and Isomorphic Labs, which draws Alphabet's two research fronts closer together and reinforces the reading that the company treats applied science as central to its AI strategy, not a side project.

The limits of this story

An investment round is not a drug approval or a product on the market. The pharmaceutical development cycle is long, expensive and subject to human clinical trials that can take years and fail at any stage. Isomorphic Labs' statement talks about accelerating scientific breakthroughs and candidates in development, without promising a launch timeline for any specific medicine. Any expectation of immediate clinical results has no support in this news.

MaxAssistant's assessment

The investment confirms that appetite for AI applied to concrete scientific problems remains strong, even in a year marked by debate over excessive spending on language model infrastructure. For anyone following the AI market, the relevant signal is not today's announcement, but what Isomorphic Labs actually shows in results over the next clinical research cycles, the real test of whether the money bought genuine progress.

Sources

Demis Hassabis on X: Series C round announcement; Isomorphic Labs: official Series C statement.